Key clinical point: In previously treated patients with metastatic castration-resistant prostate cancer (mCRPC), cabazitaxel significantly improved pain response, prolonged time to pain progression and reduced the risk of symptomatic skeletal events vs abiraterone or enzalutamide.

Major finding: Confirmed pain response was observed in 46% of patients receiving cabazitaxel and 19% of patients receiving abiraterone or enzalutamide (P less than .0001). Cabazitaxel vs abiraterone or enzalutamide significantly prolonged the median time to pain progression (hazard ratio [HR], 0.55; P = .035) and the median time to symptomatic skeletal events (HR, 0.59; P = .050).

Study details: In a phase 4 study, previously treated patients with mCRPC were randomly assigned to either cabazitaxel (n = 129) or abiraterone/enzalutamide (n = 126).

Disclosures: The study was funded by Sanofi. C Wülfing, Á Sverrisdóttir, C Theodore, S Feyerabend and G Facchini declared no conflicts of interests. The remaining authors reported ties with various pharmaceutical companies.